Alexion reports positive asfotase alfa interim results for infants
This article was originally published in Scrip
Investors had another ho-hum reaction to good news for asfotase alfa from Alexion Pharmaceuticals after the company reported interim data from an open-label Phase II study that showed statistically significant improvements in skeletal mineralization after 24 weeks of treatment for 13 infants (p=0.001) suffering from the life-threatening genetic disease hypophosphatasia (HPP).
You may also be interested in...
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.